Marine alkaloids (-)-pictamine and (-)-lepadin B block neuronal nicotinic acetylcholine receptors

Biological and Pharmaceutical Bulletin

Volumn 28, Issue 4, 2005, Pages 611-614

  Tsuneki, Hiroshi ^a   You, Yueren ^a   Toyooka, Naoki ^a   Sasaoka, Toshiyasu ^a   Nemoto, Hideo ^a   Dani, John A ^b   Kimura, Ikuko ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Ascidians alkaloid; Nicotinic receptor; Pictamine; Xenopus oocyte

Indexed keywords

ALKALOID DERIVATIVE; LEPADIN B; NICOTINIC RECEPTOR; PICTAMINE; PROSAFRININE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ASCIDIACEA; CLAVELINA LEPADIFORMIS; CLAVELINA PICTA; CYTOTOXICITY; DOSE RESPONSE; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; MALE; NONHUMAN; OOCYTE; RECEPTOR BLOCKING;

ALKALOIDS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HETEROCYCLIC COMPOUNDS, 2-RING; INHIBITORY CONCENTRATION 50; MEMBRANE POTENTIALS; NICOTINIC ANTAGONISTS; OOCYTES; QUINOLINES; RECEPTORS, NICOTINIC; UROCHORDATA; XENOPUS LAEVIS;

EID: 21144451387     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.28.611     Document Type: Article

References (27)

1. Changeux J. P., Bertrand D., Corringer P. J., Dehaene S., Edelstein S., Léna C., Le Novère N., Marubio L., Picciotto M., Zoli M., Brain Res. Brain Res. Rev., 26, 198-216 (1998).
2. Jones S., Sudweeks S., Yakel J. L., Trends Neurosci., 22, 555-561 (1999).
3. Dajas-Bailador F., Wonnacott S., Trends Pharmacol. Sci., 25, 317-324 (2004).
4. Lindstrom J., "Ion Channels," Vol. 4, ed. by Narahashi T., Plenum Press, New York, 1996, pp. 377-450.
5. Elgoyhen A. B., Vetter D. E., Katz E., Rothlin C. V., Heinemann S. F., Boulter J., Proc. Natl. Acad. Sci. U.S.A., 98, 3501-3506 (2001).
6. Clarke P. B., Prog. Brain Res., 145, 253-260 (2004).
7. Weiland S., Bertrand D., Leonard S., Behav. Brain Res., 113, 43-56 (2000).
8. Dani, J. A., Biol. Psychiatry, 49, 166-174 (2001).
9. Hogg R. C., Bertrand D., Bioorg. Med. Chem. Lett., 14, 1859-1861 (2004).
10. Blesa R., Dement. Geriatr. Cogn. Disord., 11, (Suppl. 1), 28-34 (2000).
11. Maelicke A., Schrattenholz A., Samochocki M., Radina M., Albuquerque E. X., Behav. Brain Res., 113, 199-206 (2000).
12. Palmer A. M., Trends Pharmacol. Sci., 23, 426-433 (2002).
13. Zhang L., Zhou F.-M., Dani J. A., Mol. Pharmacol., 66, 538-544 (2004).
14. Daly J. W., Garraffo H. M., Spande T. Ḟ., "Alkaloids: Chemical and Biological Perspectives," Vol. 13, ed. by Pelletier S. W., Pergamon Press, New York, 1999, pp. 1-161.
15. Tsuneki H., You Y., Toyooka N., Kagawa S., Kobayashi S., Sasaoka T., Nemoto H., Kimura I., Dani J. A., Mol. Pharmacol., 66, 1061-1069 (2004).
16. Faulkner D. J., Nat. Prod. Rep., 18, 1-49 (2001).
17. Toyooka N., Okumura M., Takahata H., Nemoto H., Tetrahedron, 55, 10673-10684 (1999).
18. Toyooka N., Yotsui Y., Yoshida Y., Momose T., Nemoto H., Tetrahedron, 55, 15209-15224 (1999).
19. Toyooka N., Yoshida Y., Yotsui Y., Momose T., J. Org. Chem., 64, 4914-4919 (1999).
20. Vernino S., Amador M., Luetje C. W., Patrick J., Dani J. A., Neuron, 8, 127-134 (1992).
21. Champtiaux N., Gotti C., Cordero-Erausquin M., David D. J., Przybylski C., Léna C., Clementi F., Moretti M., Rossi F. M., Le Novère N., McIntosh J. M., Gardier A. M., Changeux J. P., J. Neurosci., 23, 7820-7829 (2003).
22. Galzi J. L., Changeux J. P., Neuropharmacology, 34, 563-582 (1995).
23. Rodrigues-Pinguet N., Jia L., Li M., Figl A., Klaassen A., Truong A., Lester H. A., Cohen B. N., J. Physiol., 550, 11-26 (2003).
24. Alkondon M., Albuquerque E. X., J. Pharmacol. Exp. Ther., 265, 1455-1473 (1993).
25. Ringler P., Kessler P., Menez A., Brisson A., Biochim. Biophys. Acta, 1324, 37-46 (1997).
26. Watters D. J., Van Den Brenk A. L., Toxicon, 31, 1349-1372 (1993).
27. Kubanek J., Williams D. E., Dilip de Silva E., Allen T., Andersen R. J., Tetrahedron Lett., 36, 6189-6192 (1995).